AzurRx BioPharma, Inc. (NASDAQ:AZRX) traded at $0.84 at last check on Tuesday, May 04, made a downturn move of -5.81% on its previous day’s price.
Looking at the stock we see that its previous close was $0.89 and the beta (5Y monthly) reads 1.5 with the day’s price range being $0.8201 – 0.8930. The company has a trailing 12-month PE ratio of 0. In terms of its 52-week price range, AZRX has a high of $2.63 and a low of $0.61. The company’s stock has gained about -12.25% over that past 30 days.
AzurRx BioPharma, Inc. has a market cap of $69.45 Million and is expected to release its quarterly earnings report on August 13, 2019. With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the AZRX stock to lose ahead of the earnings release. Estimates by analysts give the company expected earnings per share (EPS) of -$0.07, with the EPS growth for the year raised at -$0.27 for 2021 and -$0.18 for next year. These figures represent -0.77% and -0.33% growth in EPS for the two years respectively.
On the other hand, looking at the outlook for the AZRX stock, short term indicators assign the stock an average of 100% Sell, while medium term indicators assign it an average of Hold. Long term indicators on average place the stock in the category of 50% Sell.
Based on estimates by 4 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 1 have rated the AzurRx BioPharma, Inc. (AZRX) stock as a Hold, while 3 rate it as a Buy. None analyst(s) rate it as outperform while none of them rated it as underperform, whereas none suggest the stock as a Sell. The stock has an overall rating of Overweight and investors could take advantage and scoop up stock of the company.
Looking further, we note that the PEG ratio for the AZRX stock currently stands at 0, and the most recent price level today is -4.98% off its SMA20 and -27.97% from its 50-day simple moving average. The RSI (14) is pointing at 40.1 while the volatility over the past week is 9.23% and drops to 8.56% over the past one month. The beta value is 1.5, while the average true range (ATR) is currently pointing at 0.1. The average price target for the stock over the next 12 months is $3.5, with the estimates having a low of $2.5 and a high of $5. These price ends are 197.62% and +495.24% off the today’s price level respectively, although investors could be excited at the prospect of a +257.14% if the AZRX share price touches on the median price of $3.
Let’s briefly compare AzurRx BioPharma, Inc. (AZRX) stock to its peers. We find that today’s price change of -5.81% and +47.33% over the past 12 months for AZRX competes that of Bristol-Myers Squibb Company (BMY), which has seen its stock price rise 0.19% in the latest trading session and is +5.34% over the last one year. Another of its peers Amgen Inc (AMGN) has climbed 0.07% today, and was +6.23% up over the past year, while Gilead Sciences Inc (GILD) is also down -5.81% yet, while its price remains in the green at 47.33% over the same period. AzurRx BioPharma, Inc. has a P/E ratio of 0 compared to Bristol-Myers Squibb Company’s 0 and Amgen Inc’s 20.32. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at -1.21% and -0.62%, respectively, in early deals.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Coming back to AzurRx BioPharma, Inc. (NASDAQ:AZRX), we note that the average 3-month trading volume was 9.93 Million, while that of the preceding 10-day period stands at 9.38 Million. Current shares outstanding are 74.44 Million.
According to data from Thomson Reuters, insiders hold 1.03% of the company’s shares while institutions hold 2.61%. The data shows that short shares as of April 14, 2021, stood at 1.83 Million at a short ratio of 0.31. This represents a 2.46% short interest in shares outstanding on April 14, 2021. Shares short dropped in April from the previous month at 669.09 Million. Investors should be worried about this stock as its upside potential is weak, with today’s price pushing the stock -7.73% down in year-to-date price movement.